Pelthos Therapeutics Pivots to Gene Therapy Amidst Liquidity Squeeze

DURHAM, NC – November 12, 2026 – Pelthos Therapeutics’ third-quarter financial results offer a revealing look at the shifting economics of the biopharmaceutical industry. The commercial-stage company is exhibiting robust year-over-year growth for its flagship molluscum contagiosum treatment, Zelsuvmi. Yet, beneath the top-line volume surge lies a sequential revenue plateau and a tightening liquidity runway. In response, Pelthos is executing a high-stakes strategic pivot, announcing a merger with Castle Creek Biosciences that will transition the company from infectious dermatology into the complex, capital-intensive arena of rare pediatric cell and gene therapy.

The Growth Illusion and Payer Realities

Zelsuvmi’s commercial trajectory serves as a classic 2026 case study in pharmaceutical economics. The volume is undeniably present—dispensed units jumped 365% year-over-year to 12,384 in the third quarter, driven by nearly 5,000 unique prescribers. Cumulatively, the drug has treated over 31,000 patients and generated $57.5 million since its launch in July 2025. Third-quarter net product revenue hit $15.2 million, a 114% increase from the same period last year.

However, the revenue engine is showing signs of friction. That $15.2 million figure represents a 1% decline from the second quarter of 2026, despite a 4% sequential increase in unit volume. This plateau exposes the double-edged sword of modern formulary access. To secure coverage for 127 million commercial lives and 100% of Medicaid lives, Pelthos has had to concede significant pricing power to Pharmacy Benefit Managers (PBMs).

During the third quarter, the company’s gross-to-net (GTN) ratio crept up to 31.5%, a direct result of a major PBM agreement that added 24 million covered lives without prior authorization requirements. While this frictionless access is a definitive win for patients and physicians, it forces the company to rely on massive volume scaling to offset margin compression. Management anticipates GTN ratios settling in the mid-30% range moving forward. In today’s healthcare landscape, securing broad access often means trading unit profitability for market share, making the path to overall profitability steeper than top-line growth suggests.

A Strategic Leap into Cell and Gene Therapy

This margin friction contextualizes the company's abrupt strategic pivot. On October 30, Pelthos announced a definitive agreement to merge with Castle Creek Biosciences, a transaction slated to close in the first quarter of 2027. This is not merely an acquisition; it is a fundamental corporate transformation. Pelthos is evolving from a company marketing standard topical treatments for common skin infections into a developer of rare pediatric cell and gene therapies.

Castle Creek brings D-Fi, a late-stage, redosable, gene-modified cell therapy targeting dystrophic epidermolysis bullosa (DEB). DEB is a devastating genetic skin blistering disorder characterized by profound unmet medical needs. By targeting DEB, Pelthos is entering the lucrative but highly complex orphan drug market, where pricing power remains relatively insulated from the aggressive discounting seen in primary care and standard dermatology.

“This transformative merger brings together two complementary platforms across different therapeutic modalities and has significant upside potential through Castle Creek’s fibroblast-based cell and gene therapy technology, and its lead candidate, D-Fi, which has the potential to become a blockbuster franchise in dystrophic epidermolysis bullosa, or DEB,” Scott Plesha, CEO of Pelthos, stated in the earnings release.

Navigating a Tight Liquidity Runway

The transition from standard topicals to gene therapy is fraught with operational and financial perils. Cell therapies require intricate, capital-intensive manufacturing and highly specialized commercial infrastructure. Integrating Castle Creek's fibroblast technology with Pelthos's existing Nitricil platform will severely test the bandwidth of a management team currently focused on driving Zelsuvmi prescriptions and preparing for two more product launches in 2027.

The most pressing concern is liquidity. Pelthos ended the third quarter with just $17.7 million in cash and cash equivalents. While the net loss narrowed to $7.9 million—aided significantly by a $4.1 million non-cash gain on convertible debt fair value—the balance sheet reveals a negative stockholders' equity of $6.2 million. This represents a continued deterioration from the negative $1.5 million reported in the second quarter.

To bridge the capital gap, Pelthos drew an additional $10.0 million from its amended venture loan facility with Horizon Technology Finance in late October, bringing its total outstanding debt to $40.0 million. The terms of this facility are stringent. To unlock a final $10.0 million tranche before the end of 2027, Pelthos must achieve a trailing twelve-month net revenue of at least $70.0 million. With sequential growth for Zelsuvmi stalling, hitting that covenant will require flawless commercial execution in the coming quarters.

The financial tightrope is further complicated by recent accounting hurdles. In August 2026, the company restated its first-quarter financials due to a misapplication of fair-value guidance for convertible debt, prompting management to flag conditions that could raise substantial doubt about the company's ability to continue as a going concern. While the Horizon debt extension provides immediate breathing room, it does not cure the underlying capital deficit required to launch two new drugs—Xepi in Q1 2027 and Xeglyze in Q3 2027—while simultaneously funding late-stage cell therapy integration.

Competing in the DEB Arena

If Pelthos can navigate the financial squeeze, the DEB market offers a compelling, albeit highly competitive, frontier. The landscape was fundamentally altered in May 2023 with the FDA approval of Krystal Biotech's Vyjuvek, a topical gene therapy that delivers a functional COL7A1 gene directly to patient wounds. Vyjuvek established the commercial viability of DEB treatments, but it also set a high efficacy and safety bar.

Castle Creek’s D-Fi attempts to differentiate itself as a redosable cell therapy. While specific head-to-head clinical data remains pending, the chronic and severe nature of DEB means the market can likely support multiple therapeutic modalities. Redosable cell therapies could offer distinct advantages in long-term disease management, particularly if they provide durable engraftment of healthy fibroblasts that continuous topical applications cannot match.

In the broader context of the 2026 biopharmaceutical landscape, Pelthos’s situation is emblematic of a wider industry trend. We are seeing a distinct bifurcation in how therapies are valued. On one side, mass-market treatments face relentless downward pricing pressure from consolidated payer networks. On the other, highly specialized therapies for rare diseases continue to command premium pricing and robust investor enthusiasm. By acquiring Castle Creek, Pelthos is attempting to straddle this divide, using the cash flow from its standard dermatology portfolio to fund a high-upside venture in genetic medicine.

This dual-track strategy requires a delicate balancing act. The commercial team must aggressively negotiate with regional health plans to maintain Zelsuvmi’s volume growth without entirely sacrificing net revenue per unit. Simultaneously, the clinical and regulatory teams must integrate Castle Creek’s operations seamlessly, ensuring that D-Fi remains on track for its critical milestones. Any disruption in the supply chain or delay in the planned 2027 rollouts of Xepi and Xeglyze could trigger a liquidity crisis long before the gene therapy pipeline can deliver its promised value. The coming year will dictate whether this pivot is a masterstroke of corporate repositioning or a bridge too far for a balance sheet already under severe strain.